Matrix metalloproteinase-2 (MMP-2) has pivotal role in the degradation of extracellular matrix, and thereby enhances the invasive, proliferative and metastatic potential in cancer. Knockdown of MMP-2 using MMP-2 small interfering RNA (pM) in human glioma xenograft cell lines 4910 and 5310 decreased cell proliferation compared with mock and pSV (scrambled vector) treatments, as determined by 5-bromo-2 0 -deoxyuridine incorporation, Ki-67 staining and clonogenic survival assay. Cytokine array and western blotting using tumor-conditioned media displayed modulated secretory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-a, angiogenin, vascular endothelial growth factor and PDGF-BB in MMP-2 knockdown cells. Further, cDNA PCR array indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells. Mechanistically, MMP-2 is involved in complex formation with a5 and b1 integrins and MMP-2 downregulation inhibited a5b1 integrin-mediated Stat3 phosphorylation and nuclear translocation. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays showed inhibited Stat3 DNA-binding activity and recruitment at CyclinD1 and c-Myc promoters in pM-treated cells. In individual experiments, IL-6 or siRNA-insensitive MMP-2 overexpression by pM-FL-A141G counteracted and restored the pM-inhibited Stat3 DNA-binding activity, suggesting IL-6/Stat3 signaling suppression in pM-treated 4910 and 5310 cells. MMP-2/a5b1 binding is enhanced in human recombinant MMP-2 treatments, resulting in elevated Stat3 DNA-binding activity and recruitment on CyclinD1 and c-Myc promoters. Activation of a5b1 signaling by Fibronectin adhesion elevated pM-inhibited Stat3 phosphorylation whereas blocking a5b1 abrogated constitutive Stat3 activation. In vivo experiments with orthotropic tumor model revealed the decreased tumor size in pM treatment compared with mock or pSV treatments. Immunofluorescence studies in tumor sections corroborated our in vitro findings evidencing high expression and co-localization of MMP-2/a5b1, which is decreased upon pM treatment along with significantly reduced IL-6, phospho-Stat3, CyclinD1, c-Myc, Ki-67 and PCNA expression levels. Our data indicate the possible role of MMP-2/a5b1 interaction in the regulation of a5b1-mediated IL-6/Stat3 signaling activation and signifies the therapeutic potential of blocking MMP-2/a5b1 interaction in glioma treatment.
INTRODUCTION
High proliferative and invasive behavior of malignant tumors of the central nervous system is responsible for inefficacy of existing treatment procedures. 1 Glioma malignancy is, in part, attributed to the action of a group of metallo-, cysteine and serine proteases, which degrade ECM (extracellular matrix) proteins. 2, 3 Matrix metalloproteinase-2 (MMP-2) is a 72 kDa, Zn þ 2 -dependent secreted endopeptidase and its elevated expression is highly correlated with increased tumor progression implicating its multiple roles in tumor cell proliferation, migration, invasion and angiogenesis. 4 Enhanced glioma malignancy is also characterized by aberrant expression of integrins, which comprises 18a and 8b subunits that combine to form about 24 heterodimers, and their dynamic interactions with ECM molecules generate intracellular oncogenic signaling events. 5 Several studies demonstrated the significance of MMP-2/aVb3 integrin liaison in the regulation of tumor proliferation, invasion and angiogenesis. 6 --9 Along with aVb3, integrin a5b1 (Very Late Antigen 5, VLA5) is also implicated to enhance tumor progression by triggering various survival signaling pathways including PI3K-AKT, Bcl-2 and nuclear factor (NF)-kB. 10 --14 Recently, accumulating evidences show a5b1-mediated modulation of MMP-2 activity and suggest a direct interaction between MMP-2 and a5 integrin in melanoma and breast cancer cells. 15 --17 Migrating astrocytes show co-localization of MMP-2 with b1 integrin at the cell periphery, indicating its significance in pericellular proteolysis. 18 However, knowledge on MMP-2/a5b1 interaction and its role in the regulation of a5b1-mediated signaling pathways in glioma is still lacking.
Tumor progression is orchestrated by an intricate set of cytokines, which have key roles in attenuation of apoptosis and enhanced invasion and metastases of cancer tissue. 8, 19 Interleukin-6 (IL-6) belongs to a family of cytokines participating in gp130 receptor signaling in the activation of Janus kinase (JAK)/ Stat3 activation in several cancers including glioblastoma and high circulating IL-6 levels are associated with increased tumor malignancy. 20 --24 Upon stimulation, IL-6 binds to sIL-6R, which then induces gp130 dimerization and JAKs phosphorylation, which facilitate recruitment, phosphorylation and subsequent nuclear translocation of STAT (signal transducers and activators of transcription) proteins. 25 Persistent Stat3 activation is a hallmark of several human cancers, and it acts as a critical transcriptional mediator of oncogenic signaling, enhancing cancer cell proliferation, migration and angiogenesis via activation of its target genes, which encode anti-apoptotic and angiogenic factors. 26 --30 High Stat3 activity is correlated with enhanced MMP-2 activity, which is itself a Stat3-target gene and blockade of Stat3 activity by dominant-negative-Stat3 or treatment with JAK-inhibitor significantly reduced MMP activity. 31 --33 Specific inhibition of the Stat3 signaling cascade inhibited invasion and migration in glioma and tumor growth in lung cancer. 22, 34, 35 Our previous studies with MMP-2 knockdown in human lung cancer and glioma cell lines inhibited proliferation, invasion and migration and led to apoptotic cell death. 36 Based on the complexity of integrin signaling and our preliminary cytokine expression analysis of the culture supernatants (which revealed a significant suppression of several cytokines under MMP-2-depleted conditions), we sought to determine the possible modulation of b1 integrin-mediated IL-6/Stat3 activation and its implication in MMP-2.siRNA-induced cell death in human glioma xenograft cell lines. Taken together, the detailed analysis of constitutive Stat3 inhibition with MMP-2.siRNA and a5b1 blocking treatments confirmed the substantial interaction of MMP-2/a5b1 integrin by immunocomplex formation and further elucidates the mechanistic role of MMP-2/a5b1 in IL-6/Stat3 signaling activation in glioma.
RESULTS

MMP-2 knockdown inhibited human glioma xenograft cell proliferation
The significant inhibition in MMP-2 expression and activity in pMtreated 4910 and 5310 cells in comparison to mock-and pSV (scrambled vector)-treated cells at 48 h was confirmed by RT --PCR, western blotting and gelatin zymography (Supplementary Figure S1A) . 5-Bromo-2 0 -deoxyuridine (BrDU) proliferation assay at pre-determined time intervals indicated that the pM-transfected cells showed a time-dependent decrease in proliferation rate from 24 to 96 h compared with mock-and pSV-treated cells. A significant inhibition in proliferation up to 56.5% (72 h) and 66.1% (96 h) was documented in pM-treated 4910 cells. The 5310 cells displayed 56.2 and 65.4% decrease in BrDU incorporation at 72 and 96 h of post-transfection, respectively ( Figure 1a ). Immunofluorescence showed decreased nuclear Ki-67 staining in pM-treated cells compared with mock-and pSV-treated controls (Figure 1b) . Further, monolayer colony formation assay showed severe hindrance in the colony forming efficiency of pM-treated cells (Figure 1c) . After 10 days, there was up to X70.8 and X71.2% inhibition in colony formation in pM-treated 4910 and 5310 cells, respectively, when compared with their control counterparts (Figure 1d ). MMP-2 downregulation decreased a5 and b1 integrin expression and MMP-2/a5b1 interaction A possible interaction between MMP-2 and a5b1 has been implicated in the modulation of MMP-2 activity and subsequent tumor cell invasion has been reported previously in melanoma and breast cancer cells. 15 --17 Several reports suggested the positive regulation of survival signaling by a5b1 integrin and targeting by a5b1 antagonists decreased proliferation in tumor cells. 37, 38 Based on the previous reports suggesting possible MMP-2/a5b1 integrin interaction and with the prominent proliferation inhibition upon MMP-2 downregulation in our studies, we next checked the effect of MMP-2 knockdown on a5 and b1 integrin expression levels. Both a5 and b1 mRNA and protein expression levels were remarkably reduced and densitometric analysis showed up to B60% reduction in pM-treated 4910 and 5310 cells compared with control counterparts (Supplementary Figure S1B; Figure 2a) . Immunoprecipitation experiments showed immunocomplex formation of MMP-2/a5 and MMP-2/b1 by physical interaction in un-treated 4910 and 5310 cells whereas pM-treated cells show decreased interaction (Figure 2b) . Eventually, co-IP blots were re-probed with antibody used for immunoprecipitation to check the band specificity, input samples were subjected to western blotting, and GAPDH levels were estimated to confirm equal loading. Confocal studies signified a strong co-localization of MMP-2 with a5b1 in mock-and pSVtreated 4910 and 5310 cells. On the other hand, pM-transfected cells showed noticeable inhibition in MMP-2 and a5b1 expression, which subsequently led to decreased MMP-2/a5b1 co-localization. Densitometric analysis showed significant reduction (up to B67%) in MMP-2/a5b1 co-localization upon pM treatment for 48 h (Figure 2c ). To further verify the MMP-2/a5b1 interaction, we overexpressed siRNA-insensitive Myc-tagged MMP-2 (pM-FL-A141G) in 4910 and 5310 cells. MMP-2 overexpression was confirmed by western blotting analysis in comparison to mock or pEV controls (Supplementary Figure S1C) . Immunoprecipitation and probing with anti-MMP-2 and anti-Myc antibodies confirmed enhanced MMP-2/a5b1 binding in pM-FL-A141G-treated cells compared with mock and pEV control counterparts (Supplementary Figure S1C ). siRNA-insensitive MMP-2 overexpression upon pM-FL-A141G treatment was confirmed by western blotting (Supplementary Figure S1D) . The prominent decreases in MMP-2 and a5b1 expression levels and interaction in pM treatments and enhancement of MMP-2/a5b1 binding by pM-FL-A141G treatment suggests a role of MMP-2 binding in a5b1 integrin-mediated intracellular signaling. The high expression and co-localization of MMP-2 and a5b1 integrin was also evident in the human glioblastoma tissues implicating the significance of MMP-2/a5b1 binding in glioma malignancy whereas normal brain tissues did not show noticeable expression and MMP-2/a5b1 co-localization (Supplementary Figure S2) . MMP-2 downregulation altered cytokine secretion pattern in glioma xenograft cells The tumor microenvironment is characterized by enhanced cytokine levels, which in turn activates signaling pathways facilitating exacerbation of proliferation, differentiation and invasion of the tumor cells. 19 With the prominent reduction of proliferation in MMP-2 knockdown cells, we next sought to evaluate the secretory cytokine profile in the extracellular milieu. As described in Materials and methods, conditioned media (CM) consisting of secretory cytokines and growth factors was collected from pSV-and pM-treated cells and subjected to cytokine array, which indicated a prominent modulation in cytokine release pattern with an inhibition in several cytokines including GM-CSF (granulocyte-macrophage colony-stimulating factor), IL-6, IL-8, IL-10, TNF-a (tumor necrosis factor-a), angiogenin, VEGF (vascular endothelial growth factor) and PDGF-BB in MMP-2 knockdown cells. Densitometric analysis of cytokine array showed significant (Po0.01) and moderate (Po0.05) differences among pSV and pM treatments. Upon pM treatment, a significant inhibition in GM-CSF, IL-6, IL-8, IL-10, VEGF and PDGF-BB (at Po0.01) and a moderate decrease in TNF-a (Po0.05) was documented in both 4910 and 5310 cells (Figure 3a ). Angiogenin showed a noticeable inhibition of up to B71% in 4910 and a moderate loss up to B48% in 5310 cells, respectively. This noticeable reduction in the secretion levels of GM-CSF, IL-6, IL-8, IL-10, TNF-a, angiogenin, VEGF, PDGF-BB was further confirmed by subjecting CM to western blot analysis in both 4910 and 5310 cell lines (Figure 3b ). The significant loss of cytokine secretion is in correlation with the reduction of cellular expression levels of cytokines IL-6, IL-8 and IL-10 in MMP-2 knockdown 4910 and 5310 cells (Figure 3c ). MMP-2 depletion altered JAK/STAT pathway gene expression IL-6 is one of the abundantly expressed cytokine in the tumor microenvironment, which binds to gp130 receptor and subsequently activates JAK/STAT survival signaling. Based on the striking downregulation of cellular and secreted IL-6 levels in pM-treated cells, we further checked the possible modulation of Stat3 signaling pathway genes by performing JAK/STAT pathway PCR array and compared gene expression profiles in pSV-and pMtreated cells. The significant fold change deviation from threshold value were indicated, which included the genes encoding JAK receptor proteins, other interacting proteins and Stat3-target proteins. Among the various downregulated Stat3 signaling related genes, the essential receptor proteins, such as EGFR (epidermal growth factor receptor); IL-6ST (gp130); IL-2RG (IL-2 receptor, g); IL-1-RA (IL-10 receptor, a); IL-4R (IL-4 receptor); Tyk2 (Tyrosine kinase 2); JAK2 and Csf2rb (colony stimulating factor 2 receptor, b), showed decreased expression implying a modulation of expression of several receptor proteins in the pM treatment group of both cell lines ( Table 1) . The PCR array analysis also revealed a noticeable downregulation in Stat3-target genes encoding for c-Myc, Bcl-2L1, CyclinD1 and upregulation in Stat3 signaling suppressors including PIAS1, SOCS1, CDKI1A and PP2Aa confirming the potential negative regulation of Stat3 pathway in MMP-2-depleted cells.
MMP-2 depletion inhibited constitutive Stat3 activation in glioma xenograft cells Western blotting showed considerable decrease in gp130, phospho-JAK1, JAK1, phospho-JAK2, JAK2 and phospho-Stat3 (Tyr705 and Ser727) expression levels with no noticeable change in total Stat3 in pM-treated 4910 and 5310 cells whereas constitutive Stat3 activation were documented in both mockand pSV-treated controls (Figure 4a ). Even though the inhibition in Stat3 phosphorylation was evident at 24 h, we observed further decrease at 48 h post-pM-transfection, indicating that this effect was time dependent (data not shown). Fluorescence microscopy showed conspicuous reduction in phospho-Stat3 expression and subsequent nuclear translocation in MMP-2 knockdown cells. cells were seeded in 100 mm plates and were treated with mock, pSV and pM as described above. Plates were incubated for 10 days to allow colony formation, and stained with Hema-3. (d) Colonies were counted under light microscope and percentage of colony formation was represented as mean±s.e. obtained form three independent experiments and significance was denoted by *Po0.01.
In contrast, mock-and pSV-treated cells show high expression of phospho-Stat3 distributed throughout cytoplasm, with prominent nuclear localization (Figure 4b ). To further assess the effect of pM on Stat3 DNA-binding activity, electrophoretic mobility shift assay (EMSA) was performed which revealed a high Stat3 activity in both mock-and pSV-treated 4910 and 5310 controls. Conversely, a prominent decrease in DNA-binding activity was evidenced in 48 h pM-transfected cells implying that the loss of MMP-2 leads to suppression of constitutive STAT3 activation (Figure 4c) . Further, the recruitment of Stat3 was assessed by ChIP (chromatin Figure 2 . Effect of MMP-2 downregulation on a5 and b1 integrin expression and MMP-2/a5b1 complex formation. (a) Whole cell lysates were subjected to western blotting to check the expression levels of a5 and b1 integrins and relative expression levels were quantified using ImageJ (NIH) and plotted as mean ± s.e. values from three replicates and statistical significance was represented by *Po0.01. (b) Whole cell lysates (200 mg) were immunoprecipitated with antibodies against Nsp-IgG, a5 and b1 integrin using mMACS protein G microbeads and MACS separation columns and immunoprecipitates were subjected to western blotting. The co-IP blots were stripped and re-probed with respective antibody used for immunoprecipitation. Input samples (whole cell lysates without immunoprecipitation) were subjected to western blot analysis where GAPDH probing was used to check equal loading. (c) In all, 4910 and 5310 cells were seeded in two-well chamber slides (2 Â 10 3 /well) and transfected for 48 h as described in Materials and methods. Cells were fixed, permeabilized and incubated with antibodies specific for a5b1 and MMP-2 (1:100 dilution) for 2 h at room temperature followed Alexa Fluor secondary antibodies for 1 h, DAPI stained and mounted. Nsp-IgG staining served as negative control (Insets). Representative confocal microscopic pictures in randomly selected microscopic fields of three independent experimental replicates were shown. Relative florescence levels representing MMP-2/a5b1 co-localization were estimated by ImageJ 1.42 (NIH) and arbitrary units were plotted in the bar diagram as mean±s.e. and significant difference among different treatment groups was denoted by *Po0.01. immunoprecipitation) assay, which showed a strong occupancy of Stat3 at CyclinD1 and c-Myc promoters in both mock-and pSVtreated 4910 and 5310 cells. In contrast, MMP-2 suppression using pM noticeably inhibited the Stat3 recruitment on to CyclinD1 and c-Myc promoters suggesting the downregulation of these proteins ( Figure 4d ). Western blotting showed a remarkable downregulation in Stat3-target proteins CyclinD1, c-Myc, Bcl-xL, Bcl-2 and Survivin in pM-treated 4910 and 5310 cells in comparison to control counterparts (Figure 4e ). Eventually, to rule out the offtarget effects of pM on negative regulation of a5b1-mediated IL-6/ Stat3 activation and proliferation in 4910 and 5310 cell lines, parallel MMP-2 knockdown experiments were also performed using pM-1 (siRNA in pcDNA3.0 targeting the 1073 --1094 position in MMP-2 cDNA), pM-2 (sc-29398) and siRNA-specific SVs pSV-1 and pSV-2. Comparable to pM-induced MMP-2 knockdown, pM-1 and pM-2 treatments also resulted in a noticeable decrease in proliferation compared with respective pSV-1 and pSV-2 controls (Supplementary Figure S3A) . The CM from pM-1 and pM-2-treated cells showed drastic reduction in the secreted levels of IL-6, IL-8 and IL-10 in corroboration with the downregulation of cellular expression levels of a5 integrin, b1 integrin, IL-6, phospho-Stat3 (Supplementary Figure S3B and C). The effect of MMP-2 downregulation was also evaluated in another two human glioma cell lines, U251 and U87, which confirmed the noticeable decrease in proliferation and suppression of a5, b1, IL-6, expression and JAK1, JAK2 and Stat3 phosphorylation levels (Supplementary Figure S4 ).
IL-6 mediates pM-induced inhibition of constitutive Stat3 activation
To further evaluate the significance of MMP-2.siRNA-induced IL-6 inhibition on subsequent JAK/Stat3 pathway attenuation, we overexpressed IL-6 and confirmed the enhanced mRNA and protein expression levels of IL-6 in transfected 4910 and 5310 cells after 24 h (Supplementary Figure S5A) . There was remarkable elevation of gp130, phopsho-JAK1, JAK1, phospho-JAK2, JAK2 and phospho-Stat3 expression levels in cells treated with pIL-6 alone or pSV þ pIL-6 compared with either mock-or pSV-treated cells. In contrast, the expression levels of IL-6, phospho-JAK2 and phoshoStat3 in pM þ IL-6 treatments were elevated when compared with pM treatment alone and lesser in comparison to either pIL-6 or pSV þ pIL-6 treatments, implying a significant reversal of phosphoStat3 inhibition by IL-6 overexpression in pM-treated cells. The reversal in gp130, phospho-JAK1, JAK1, phospho-JAK2, JAK2 and phospho-Stat3 expression correlated with IL-6 overexpression in pM-treated cells, further implying that the MMP-2 depletion attenuated the IL-6-mediated Stat3 activation (Figure 5a ). Corroborating previous reports showing MMP-2 as a potential Stat3-target gene, IL-6 overexpression in turn resulted in remarkable elevation in MMP-2 gelatinolytic activity, which was suppressed in pM þ pIL-6 combination treatment (Supplementary Figure S5B) . Additionally, EMSA also showed significant reversal of IL-6-induced Stat3-DNA-binding activity in pM þ pIL-6 treatment, suggesting that the loss of MMP-2 activity inhibited the IL-6-mediated Stat3 activation (Figure 5b ). Confocal microscopy also Figure 3 . Modulation of cytokine release pattern after MMP-2.siRNA (pM) treatment in 4910 and 5310 cells. (a) Tumor CM from pSV and pM treatments was collected as described in Materials and methods and subjected to western array using Ray Biotech cytokine antibody array #3 following the manufacturer's instructions. The significant change in secreted cytokines among different treatments was highlighted with surrounding boxes and represent GM-CSF, IL-6, IL-8, IL-10, TNF-a, angiogenin, VEGF and PDGF-BB. The relative signal intensity was quantified using ImageJ 1.42 software (NIH) and mean ± s.e. were plotted in the adjacent bar diagrams where significant deviation is represented by *Po0.05 and **Po0.01, respectively. (b) CM from mock, pSV and pM treatments were subjected to western blot analysis and the representative blots from three independent experiments were presented. (c) In all, 4910 and 5310 whole cell lysates were subjected to western blot analyses and densitometric values showing relative expression levels were plotted as mean±s.e. from three experimental replicates.
MMP-2 knockdown inhibits a5b1-mediated IL-6/STAT3 activation D Kesanakurti et al revealed elevation in phospho-Stat3 nuclear localization in pIL-6-treated cells compared with mock-treated cells and pM þ pIL-6-treated cells showed an expression pattern similar to either mock or pSV treatment confirming the reversal of pM-inhibited phospho-Stat3 nuclear localization in pIL-6-treated cells (Supplementary Figure S5C ). The effect of pM and pM þ pIL-6 treatments was further checked on cell proliferation using BrDU assay. IL-6 overexpression restored the pM-inhibited proliferation in pM þ pIL-6 treatment (Figure 5c ). Additionally, we observed a consistent reversal in pM-induced PARP and caspase-3 cleavage, and inhibition in CyclinD1 and c-Myc expression levels in pM þ pIL-6-treated cells, which directly indicates that the loss of MMP-2 leads to the suppression of IL-6/Stat3 proliferation signaling (Figure 5d ). Abbreviations: IL, interleukin; JAK, Janus kinase; MMP, matrix metalloproteinase; STAT, signal transducers and activators of transcription; TNF, tumor necrosis factor. Total RNA was isolated from pSV-and pM-treated 4910 and 5310 cells using TRIzol (Invitrogen) and cDNA was synthesized from 1 mg RNA. The cDNA was analyzed with human JAK/STAT signaling pathway RT 2 Profiler PCR array system using SYBR Green/fluorescein qPCR master mix (SA Biosciences). The resulting gene expression changes in the form of C t values were analyzed and converted into fold changes and compared with the web-based software package for PCR array system. The mean fold change in expression levels in pM and pSV treatments was obtained from three independent experiments. Nuclear extracts were prepared using Biovision cytoplasmic/nuclear extraction kit and subjected to EMSA using Panomics EMSA kit following the manufacturer's instructions. The mock sample was pre-incubated with STAT3a antibody for 30 min at room temperature and then loaded for supershift and representative blots from three independent repetitions were shown. (d) ChIP assay was performed in mock-, pSV-and pMtreated cells using ChIP-IT Express Magnetic Chromatin Immunoprecipitation kit following the manufacturer's protocol (Active motif ) and immunoprecipitated DNA was collected using magnetic protein G beads and the chromatin reverse cross-linked, purified and subjected to PCR to detect the Stat3 recruitment at CyclinD1 and c-Myc promoter sequences. Pre-immunoprecipitated samples were used as input controls in PCR amplification of GAPDH to monitor equal loading and IP with normal sheep IgG (Nsp-IgG) served as negative control. (e) Whole 4910 and 5310 cell lysates were subjected to western blotting and blots were re-probed with GAPDH to assure equal loading. (Figure 8a ). High expression and predominant co-localization of MMP-2 and a5b1 integrin at membrane periphery were identified in both mock-and pSV-treated tumors (Figure 8b ). In contrast, pM-treated Figure 5 . Effect of IL-6 overexpression on pM-inhibited constitutive Stat3 phosphorylation, DNA-binding activity and proliferation in glioma xenograft cells. (a) Western blotting was performed using 4910 and 5310 whole cell lysates at 48 h post-transfection. GAPDH probing was used to check equal loading. (b) Nuclear extracts were prepared using Biovision cytoplasmic/nuclear extraction kit and subjected to EMSA using Panomics EMSA kit as per the manufacturer's instructions. Representative blots from three independent repetitions were shown. For supershift analysis, mock sample was loaded after pre-incubation with STAT3a antibody for 30 min at room temperature. (c) In all, 4910 and 5310 cells were seeded (1 Â 10 3 cells/well) in 96-well plates and subjected to different treatments for 48 h as described in Materials and methods. BrDU cell proliferation assay was performed % BrDU incorporation obtained from three individual repetitions was represented as mean±s.e. and significance is shown by *Po0.05 and **Po0.01. (d) Western blotting was performed using whole cell lysates to check cleaved PARP, cleaved caspase-3, CyclinD1 and c-Myc expression levels. Blots are representative of three experimental replicates and GAPDH probing was used to confirm equal loading.
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tumors showed substantial decrease in MMP-2 and a5b1 expression, which subsequently led to decreased MMP-2/a5b1 co-localization correlating with reduced IL-6 and phospho-Stat3 expression levels (Figure 8c ). Further expression levels of proliferation markers Ki-67 and PCNA were studied to check the number of proliferating cells in sections, which revealed the severe inhibition in Ki-67 and PCNA positivity in pM-treated tumor sections whereas the mock-and pSV-treated control tumors showed high proliferating cells with intense nuclear Ki-67 and PCNA staining (Supplementary Figure S6) . The CyclinD1 and c-Myc expression was significantly decreased in pM-treated tumor sections when compared with pSV-treated control counterparts (Supplementary Figure S7) . These in vivo observations corroborate the in vitro findings confirming the role of MMP-2 in a5b1-mediated IL-6/Stat3 signaling activation in glioma. (a) After 48 h of treatment with mock, pSV, pM, pM-FL-A141G, pSV þ pM-FL-A141G, pM þ pM-FL-A141G, rhMMP-2, pSV þ rhMMP-2 and pM þ rhMMP-2 as described in Materials and methods, whole cell lysates were subjected to western blotting. Blots were representative of at least three independent repetitions and GAPDH probing confirmed equal loading. (b) Effect of MMP-2 overexpression by siRNA-insensitive pM-FL-A141G treatment or rhMMP-2 supplementation on pM-inhibited MMP-2/a5b1 integrin binding. Whole cell lysates were (200 mg each) immunoprecipitated with anti-a5b1 integrin antibody (10 ml each sample) using mMACS protein G microbeads and MACS separation columns and immunoprecipitates were subjected to western blotting. The mock sample immunoprecipitated with Nsp-IgG was loaded as the negative control. Input shows whole cell lysate (50 mg) of mock sample served as the positive control. Blots were probed with anti-MMP-2 antibody and representative blots from three independent repetitions were shown. Adjacent bar diagram shows the densitometric analyses of the relative band intensity represented as mean ± s.e. values obtained from three repetitions. The significant differences among various treatment groups were indicated by *Po0.05. IP blots were stripped and subsequently re-probed with anti-a5, anti-b1 and anti-Myc antibodies. (c) EMSA was performed using Panomics EMSA kit following the manufacturer's instructions as described in Materials and methods. The mock sample was pre-incubated with Stat3a antibody for 30 min at room temperature and loaded for supershift. Representative blots from three experimental replicates were shown. (d) ChIP assay was performed using ChIP-IT Express Magnetic Chromatin Immunoprecipitation kit following the manufacturer's protocol (Active motif ). In short, cells were fixed in 37% formaldehyde and chromatin was sheared by sonication and immunoprecipitated using anti-Stat3 antibody and normal sheep IgG (Nsp-IgG) antibodies by incubation at 4 1C for 2 --4 h on a rotor. The immunoprecipitates were collected by using magnetic protein G beads (Millipore) and the chromatin was reverse cross-linked, purified and subjected to PCR to detect the Stat3 recruitment at CyclinD1 and c-Myc promoter sequences. Pre-immunoprecipitated samples were used as input controls for PCR amplification of GAPDH and normal sheep IgG (Nsp-IgG) incubation was used for the negative control. (e) BrDU assay was performed following the manufacturer's instructions to obtain mean±s.e. values of BrDU incorporation percentage from three repetitions and significance was represented by *Po0.05 and **Po0.01.
DISCUSSION
Apoptotic cell death has a crucial role in the development of multicellular organisms, but it is also a major concern in cancer treatment as cancer is a consequence of aberrant cell proliferation thereby manipulation of the extra-and intracellular signals directing intracellular oncogenic signaling activation may serve to drive tumor cells towards cell death. 39 MMPs are the ECM remodeling proteases that act as critical mediators in tumor microenvironment changes. 2 Integrins are membrane-spanning proteins, with their extracellular domains bound to the ECM proteins while their cytoplasmic tails facilitate assembly of intracellular proteins and propagate the outside --in signaling. Among other integrins, accumulating evidences indicate the high expression of a5b1 in glioblastoma cells, suggesting its potential as a new therapeutic target. 37, 40 One of the key mechanisms of integrins is their interaction and modulation of MMP activity. 16, 17 The a5b1 integrin activates NF-kB proliferative signaling and elevates the expression of genes involved in angiogenesis and inflammation whereas Chinese hampster ovary cells expressing truncated a5Dcb1 without the cytoplasmic domain show impaired NF-kB activation, leading to cell death. 13, 41 In a recent report, Shain et al. 42 demonstrated the role of b1 integrin in IL-6-mediated Stat3 survival signaling in multiple myeloma cells. Studies on the blockade of the IL-6/Stat3 signaling pathway by anti-IL-6 receptor antibody substantially inhibited tumor progression by downregulating Stat3 signaling in human colon carcinoma cells. 43 Targeting b1 integrins with b1-inhibitory antibody significantly inhibits proliferation by apoptosis in breast cancer cells in vitro and in vivo. 44 A non-RGD-based peptide inhibitor of a5b1 integrin ATN-161 and a functional blocking a5b1 integrin antibody blocks in vivo tumor growth and metastasis in breast cancer cells. 45 The N-glycosylation of interaction-like (I-like) domain of b1 integrin is required for a5b1 heterodimer formation, and the role of a5b1 in tumor cell survival signaling has been elucidated previously. 12, 13, 38, 46 On the other hand, the a5b1 integrin functional blocking inhibitory antibody Volociximab significantly reduced tumor growth in mouse and rabbit VX2 carcinoma models. 47 Though several studies suggested the effect of various integrins on the manipulation of cytokine levels, the effect of a5b1 integrin heterodimer on IL-6 expression and its downstream signaling is unknown. A functional significance of the MMP-2/b1 integrin binding was confirmed by immunoprecipitation in the negative regulation of human endothelial cell apoptosis has been reported earlier. 48 Association between MMP-2 and a5b1 integrin by direct binding in melanoma and breast cancer cells and co-localization of MMP-2/a5b1 in migrating astrocytes has been indicated previously. 16 --18 Based on these reports, we sought to determine whether there was any direct interaction of MMP-2/a5b1 integrin by complex formation in glioma. Here, for the first time, we show significant interaction of MMP-2 with a5b1 heterodimer in human glioma xenograft cells both in vitro and in vivo. However, our coimmunoprecipitation and co-localization studies do not show direct binding between MMP-2 and a5b1 integrin but indicate that they form a complex, which may be bridged by unidentified proteins. Recent reports showed the effect of NF-kB blockade on inhibition of cancer cell adhesion via downregulation of a2, a3 and b1 integrins. 49 Previous studies on MMP-2 knockdown showed inhibition of NF-kB nuclear localization and DNA-binding activity. 50 Our present studies showing pM-inhibited b1 integrin transcriptional and protein expression suggest a possible indirect role of pM-inhibited NF-kB in the downregulation of these integrin molecules. The role of b1 integrin in enhancing IL-6-mediated Stat3 signaling in multiple myeloma has been previously elucidated. 42 Role of IL-6 in JAK/Stat3-mediated MMP-2 activation in pancreatic and glioma cancer cells and MMP-10 activation in lung adenocarcinoma cells has been reported to enhance growth and invasion.
32,51,52 Farber et al. 37 showed that the treatment with a5b1 integrin inhibitor JSM6427 does not have any effect on the cytokine release pattern in microglial cells. However, in our studies with glioma xenograft cell lines, the MMP-2 siRNA-mediated inhibition of a5b1 expression is in correlation with changes in the The 4910 and 5310 cells were transfected with mock, pSV and pM for 24 h as described in Materials and methods. Cells were detached from culture plates by trypsinization and re-plated on FN-coated plates and cultured for another 24 h. Whole cell lysates were subjected western blotting and representative blots showing expression levels of phospho-Stat3, CyclinD1 and c-Myc were obtained from three individual repetitions. (b) ChIP assay was performed using ChIP-IT Express Magnetic Chromatin Immunoprecipitation kit following the manufacturer's protocol (Active motif ) and immunoprecipitated DNA was reverse cross-linked, purified and subjected to PCR to detect the Stat3 recruitment at CyclinD1 and c-Myc promoter sequences where pre-immunoprecipitated input samples were used for GAPDH PCR amplification and normal sheep IgG (NspIgG) immunoprecipitates was loaded as negative control. (c) Cells were treated with mock, pSV, pM, rhMMP-2 and a5b1 blocking antibody for 48 h as described in Materials and methods and whole cell lysates were subjected to western blotting to determine the expression levels of IL-6, phospho-Stat3, CyclinD1 and c-Myc. Blots were stripped and re-probed with GAPDH to confirm equal loading.
cytokine release pattern in 4910 and 5310 cells, suggesting that the effects of a5b1 inhibition are cell specific. The significance of IL-6 in tumor progression has been reported. 53, 54 The specific role of MMP-2 downregulation on inhibition of a5, b1, IL-6 expression and Stat3 phosphorylation were further confirmed by employing three different MMP-2.siRNAs and this effect was also checked in U251 and U87 human glioma cell lines. Our studies with a5b1 blocking by functional blocking antibody paralleled with the effect of MMP-2 downregulation inhibiting IL-6 expression and hindered Stat3 phosphorylation and recruitment on to CyclinD1 and c-Myc promoters indicates high relevance to MMP-2/a5b1 interaction in maintaining IL-6-mediated constitutive Stat3 activation in glioma. The significant inhibition of a5b1-mediated IL-6/Stat3 activation in MMP-2 downregulation was further analyzed in vivo, which indicated significant reduction in IL-6, phospho-Stat3 levels leading to reduced tumor growth. Suppression of IL-6 and IL-8, target genes of NF-kB in MMP-2 siRNA treatment in different glioma cell lines, is in parallel with our previous observation of decreased NF-kB activation upon MMP-2 downregulation in both 4910 and 5310 cell lines. 50 Our observations on a5b1 role in the activation of IL-6-mediated Stat3 signaling activation in glioma xenograft cells also corroborate previous reports on the role of a5b1 integrin adhesion in elevating the IL-6-mediated STAT3 pathway in multiple myeloma cells. 42 In summary, our findings on MMP-2.siRNA-mediated a5b1 suppression in two human xenograft cell lines 4910 and 5310 imply that role of MMP-2 in the regulation of a5b1-mediated cellular signaling. The study provides further insights into the cooperativity between MMP-2 and a5b1 integrin by indirect physical interaction in the maintenance of constitutive IL-6-mediated Stat3 DNA-binding activity and expression of subsequent downstream effector genes, suggesting MMP-2 suppression as a potential therapeutic approach in glioma treatment.
MATERIALS AND METHODS
Cells, reagents and antibodies
Human glioma xenograft cell lines 4910 and 5310 (kindly provided by Dr David James, University of California, San Francisco) are highly invasive in mouse brain were developed and maintained in mice. 55 These cells were cultured in RPMI 1640 (Mediatech Inc., Herndon, VA, USA) medium supplemented with 10% fetal bovine serum (Invitrogen Corporation, Carlsbad, CA, USA), 50 units/ml penicillin and 50 mg/ml streptomycin (Life Technologies, Inc., Frederick, MD, USA) by incubation in a humidified 5% CO 2 chamber at 37 1C. Human glioma cell lines U251 and U87 (American Type Culture Collection, Rockville, MD, USA) were grown in RPMI 1640 medium containing glutamate (5 mM) and 5% fetal bovine serum and maintained in CO 2 incubator. We used antibodies against MMP-2, IL-6, IL-8, IL-10, a5 integrin, b1 integrin, phospho-JAK1 (Tyr1022), phospho-JAK2 (Tyr1007/1008), gp130, Stat3 (sc-482 X; Gel supershift and ChIP grade), phopsho-Stat3 (Tyr705), phospho-Stat3 (Ser727), c-Myc, CyclinD1, Bcl-x(L), Bcl-2, Survivin, Ki-67, PCNA, GAPDH and HRP/Alexa Fluor-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), caspase-3 and poly (ADP-ribose) polymerase (Cell Signal Technology, Beverly, MA, USA). Anti-integrin a5b1, clone HA5 (MAB1999) and a5b1 functional blocking antibody (MAB1969) (Millipore Inc., Billerica, MA, USA) were obtained. Human Brain Tumor Tissue Microarray, GL2082 (US Biomax, Inc., Rockville, MD, USA), IL-6 overexpression (pIL-6) plasmid (Origene Technologies, Rockville, MD, USA) and rhMMP-2 protein were also purchased for this study (EMD Biosciences, San Diego, CA, USA).
Construction of siRNA-insensitive plasmid and transient transfection treatments
Transient transfection studies were performed as described previously by Kesanakurti et al. 50 In brief, cells were transfected with pcDNA3.0 containing MMP-2.siRNA sequence (pM, targets 131 --152 nucleotides of MMP-2 cDNA) and specific scrambled siRNA sequence (pSV) cloned as described previously 50 0 -AACGG ACAAGGAGTTGGCAGT-3 0 ) by using pM-FL as a template and QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. This siRNA-insensitive plasmid with A141G mutation was verified by DNA sequencing and is designated as pM-FL-A141G. For combination treatments, at 24 h post-transfection with mock (1 Â PBS (phosphate-buffered saline)), pSV or pM, cells were further transfected with pIL-6 or pM-FL-A141G or recombinant human MMP-2 (rhMMP-2; 25 ng/ml) or a5b1 blocking antibody (10 ml/ml) were added to the medium and cells were incubated for another 24 h. The b1 integrin activation by Fibronectin (FN) adhesion was achieved by detaching the mock-, pSV-and pM-treated cells by trypsinization after 24 h of transfection and re-plating them on FN-coated culture plates and cells were incubated for another 24 h.
Semi-quantitative and quantitative PCR and PCR array
Total RNA was isolated using TRIzol reagent (Invitrogen) following the manufacturer's instructions. cDNA was synthesized from 2 mg of total RNA 
ChIP assay
ChIP assays was performed using ChIP-IT Express Magnetic Chromatin Immunoprecipitation kit following the manufacturer's protocol (Active motif, Carlsbad, CA, USA). Briefly, cells were fixed in 37% formaldehyde, and chromatin was sheared by sonication and immunoprecipitated using anti-Stat3 and Normal sheep IgG antibodies by incubation at 4 1C for 2 --4 h on a rotor. The immunoprecipitates were collected by using magnetic protein G beads (Millipore, Temecula, CA, USA), which were washed thoroughly to remove non-specific DNA binding. The chromatin was eluted from the beads, and cross-links were removed by overnight incubation at 65 1C. DNA was then purified from the beads using the chelating resin solution and about 10 ng of immunoprecipitated DNA was used to detect Stat3 binding to CyclinD1 and c-Myc promoter sequences by standard PCR. The following ChIP primers were used for c-Myc sense 5 0 -GAAGCCTGAGCAGGCGGGGCAGG-3 0 ; c-Myc antisense 5 0 -GCTTTGATCAA GAGTCCCAG-3 0 and CyclinD1 sense 5 0 -AACTTGCACAGGGGTTGTGT-3 0 ; CyclinD1 antisense 5 0 -GAGACCACGAGAAGGGGTGACTG-3 0 respectively. The amplification was maintained in a linear range by performing PCR with a serial dilution of input and various cycles (30 --40 cycles). Preimmunoprecipitated input DNA represents 5% of total chromatin used in each reaction before immunoprecipitation. Primers specific to GAPDH, 5 0 -CGGTGCGTGCCCAGTTG-3 0 and 5 0 -GCGACGCAAAAGAAGATG-3 0 were used for PCR amplification of input samples as a control to monitor equal loading and Nsp-IgG immunoprecipitates were also loaded (negative control) as described previously. 56 The amplification products were resolved on 2% ethidium bromide agarose gels and visualized under UV light and data represent three experimental replications.
Western blotting and immunoprecipitation
Western blotting and immunoprecipitation studies were performed as described previously by Kesanakurti et al. 57 Shortly, whole cell lysates were isolated using radioimmunoprecipitation assay buffer and equal amounts of protein were resolved over sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred on to PVDF membrane. Blots were incubated in respective primary and HRP-conjugated secondary antibodies followed by detection using an enhanced chemiluminescence kit (Pierce Biotechnology, Rockford, IL, USA). Equal amounts of protein (200 mg) were immunoprecipitated with antibodies against MMP-2, a5, b1, a5b1 and Nsp-IgG using mMACS protein G microbeads and MACS separation columns following the manufacturer's protocol and immunoprecipitates were subjected to western blotting.
Gelatin zymography and cytokine array
Gelatin zymographic analyses and cytokine array using tumor CM were performed as described previously. 50 Briefly, medium was aspirated from culture plates at 36 h post-transfection, 3 ml of serum-free medium was added and incubated for another 12 h at the end of which tumor CM MMP-2 knockdown inhibits a5b1-mediated IL-6/STAT3 activation D Kesanakurti et al containing the secretory proteins, cytokines and various growth factors was collected. CM was resolved over 0.1% gelatin containing sodium dodecyl sulfate polyacrylamide gels. Subsequently, gels were washed with 2.5% Triton X-100 to remove sodium dodecyl sulfate , followed by 16-to 20-h incubation at 37 1C in Tris --CaCl 2 buffer (pH 7.6), stained with Coomassie brilliant blue (0.25%) and destained to visualize the gelatinolytic activity. Cytokine array to detect the secretory levels of various cytokines present in the tumor CM obtained from pSV-and pM-treated cells was performed using a Human Cytokine Array 3 kit following the manufacturer's instructions (Ray Biotech, Norcross, GA, USA). The average signal intensity of each cytokine dotted in duplicate on the array was estimated in three independent experimental replicates and denoted as mean ± s.e., while biotin-conjugated and unconjugated IgG signals represented positive and negative signals in the analysis.
Electrophoretic mobility shift assay Nuclear proteins were isolated using Biovision nuclear/cytosol fractionation Kit (Mountain View, CA, USA) following the manufacturer's protocol. EMSA for STAT3 DNA-binding activity was performed using Panomics EMSA Kit (Panomics, Inc., Fremont, CA, USA) as described by Kesanakurti et al. 50 In brief, nuclear extracts (2 Â 10 6 cells) from different treatments were allowed to bind with biotin-end-labeled DNA in the presence of 2 Â binding buffer and poly dI-dC (deoxyinosinic-deoxy-cytidylic acid) by incubation at 15 1C for 30 min. These DNA --protein complexes were subjected to native gel electrophoresis and transferred onto Hybond-N þ membrane (Amersham, Piscataway, NJ, USA). After transfer, DNA was UV cross-linked, and activity was detected by binding with streptavidin-HRP conjugate and chemiluminescent substrate.
Cell proliferation (BrDU) and clonogenic assay Proliferation rate in cells was determined by BrDU assay (Roche Applied Science) measuring the incorporation of pyrimidine analog, BrDU during DNA synthesis. Briefly, cells were plated in 96-microwell plates, incubated overnight and subjected to different treatments as described above. Colorimetric estimation of BrDU incorporation was carried out by quantification of antibody-peroxidase reaction product at dual wavelengths of 450/540 nm using multiwell spectrophotometer as described by Ganji et al. 58 Percentage of BrDU incorporation was compared with mocktreated cells (100%) and represented as mean ± s.e. values obtained in at least three independent experiments. Monolayer colony formation assay was performed as described previously. 59 In short, about B0.5 Â 10 3 cells were seeded in 100 mm plates and different treatments were carried out in triplicate as described above and cells were continued to culture for 10 days to allow colony formation. Hema-3-stained colonies were counted under light microscope to estimate the percentage of colony formation in different treatments.
Immunocytochemical and immunohistochemical analyses
Immunocytochemical and immunohistochemical analyses were performed as described earlier. 50 Briefly, after treatments, cells in chamber slides were fixed, permeabilized and incubated with respective primary and Alexa Fluor-conjugated secondary antibodies and subsequently mounted. For nuclear counterstaining, DAPI (4 0 -6-diamidino-2-phenylindole) was used. For immunohistochemical analysis, deparaffinized tissue sections (4 --5 mm) were blocked in 3% BSA in 1 Â PBS and incubated overnight at 4 1C with respective primary antibodies followed by incubation with Alexa Fluor/ HRP-conjugated secondary antibodies for 1 h at room temperature. Sections were subsequently counterstained with DAPI, mounted and observed under confocal microscope. For DAB (3, 3 0 -diaminobenzidine) staining, hematoxylin was used for nuclear staining, mounted and pictured under light microscope.
In vivo experiments
In all, 4910 and 5310 cells (1 Â 10 6 cells per mouse) were injected sterotactically into 4-to 6-week-old female nu/nu mice to establish tumor growth as described earlier. 50 Tumors were allowed to grow for 10 days, the animals were divided into three sets (n ¼ 10) and Alzet osmotic pumps (model 2004, ALZET Osmotic Pumps, Cupertino, CA, USA) were implanted for plasmid delivery (dose: 6 --8 mg/kg body weight). The brains were excised after 60 days, fixed, paraffinized and the tumor area from every fifth hematoxylin and eosin-stained tumor section was manually estimated with the aid of a microscope attached to a computer screen, using Image Pro Discovery Program software (Media Cybernetics, Inc., Silver Spring, MD, USA). The tumor volumes were then calculated as summed tumor area on all sections multiplied by width of the sections and plotted as mean ± s.e. obtained from a group of 10 animals.
Statistical analysis
Data obtained from different sets of treatments were evaluated with oneway analysis of variance using Neumann --Keuls method of Sigmastat 3.1 (SPSS Inc., Chicago, IL, USA). Densitometric analysis was performed using ImageJ 1.42 software (NIH, Bethesda, MD, USA) and data are represented in the form of mean ± s.e. obtained from at least three independent repetitions. Significant difference among different treatment groups was denoted by *Pp0.05 and **Pp0.01.
